Canada
· Delayed Price · Currency is CAD Cytophage Technologies Statistics
Total Valuation
TSXV:CYTO has a market cap or net worth of CAD 10.79 million. The enterprise value is 10.01 million.
| Market Cap | 10.79M |
| Enterprise Value | 10.01M |
Important Dates
The next estimated earnings date is Thursday, May 1, 2025.
| Earnings Date | May 1, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
TSXV:CYTO has 53.94 million shares outstanding. The number of shares has increased by 22.29% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 53.94M |
| Shares Change (YoY) | +22.29% |
| Shares Change (QoQ) | +0.14% |
| Owned by Insiders (%) | 12.53% |
| Owned by Institutions (%) | 2.08% |
| Float | 47.18M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 2.58 |
| P/TBV Ratio | 2.58 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -1.27 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -1.71 |
Financial Position
The company has a current ratio of 4.24, with a Debt / Equity ratio of 0.38.
| Current Ratio | 4.24 |
| Quick Ratio | 4.10 |
| Debt / Equity | 0.38 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.27 |
| Interest Coverage | -50.34 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -99.19% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -39.39% in the last 52 weeks. The beta is 0.31, so TSXV:CYTO's price volatility has been lower than the market average.
| Beta (5Y) | 0.31 |
| 52-Week Price Change | -39.39% |
| 50-Day Moving Average | 0.18 |
| 200-Day Moving Average | 0.27 |
| Relative Strength Index (RSI) | 70.22 |
| Average Volume (20 Days) | 23,905 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -5.42M |
| Pretax Income | -7.91M |
| Net Income | -7.91M |
| EBITDA | -5.18M |
| EBIT | -5.42M |
| Earnings Per Share (EPS) | -0.16 |
Balance Sheet
The company has 2.36 million in cash and 1.59 million in debt, giving a net cash position of 775,219 or 0.01 per share.
| Cash & Cash Equivalents | 2.36M |
| Total Debt | 1.59M |
| Net Cash | 775,219 |
| Net Cash Per Share | 0.01 |
| Equity (Book Value) | 4.17M |
| Book Value Per Share | 0.08 |
| Working Capital | 2.19M |
Cash Flow
In the last 12 months, operating cash flow was -4.61 million and capital expenditures -1.24 million, giving a free cash flow of -5.85 million.
| Operating Cash Flow | -4.61M |
| Capital Expenditures | -1.24M |
| Free Cash Flow | -5.85M |
| FCF Per Share | -0.11 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
TSXV:CYTO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -22.29% |
| Shareholder Yield | -22.29% |
| Earnings Yield | -73.36% |
| FCF Yield | -54.22% |
Stock Splits
The last stock split was on February 9, 2024. It was a reverse split with a ratio of 0.2412662.
| Last Split Date | Feb 9, 2024 |
| Split Type | Reverse |
| Split Ratio | 0.2412662 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |